A5004698044- Cervical Cancer and HPV Research
- Reproductive tract infections research
- Genital Health and Disease
- Hepatitis B Virus Studies
- Reproductive System and Pregnancy
- Urinary Tract Infections Management
- Pelvic floor disorders treatments
- Endometriosis Research and Treatment
- Maternal and fetal healthcare
- Preterm Birth and Chorioamnionitis
- Uterine Myomas and Treatments
- Maternal and Perinatal Health Interventions
- Herpesvirus Infections and Treatments
- Pregnancy and preeclampsia studies
- Pregnancy-related medical research
- Reproductive Physiology in Livestock
- Urinary and Genital Oncology Studies
- Immunotherapy and Immune Responses
- Ectopic Pregnancy Diagnosis and Management
- Endometrial and Cervical Cancer Treatments
- Gynecological conditions and treatments
- Prenatal Screening and Diagnostics
- Reproductive Health and Contraception
- Animal Virus Infections Studies
- Urticaria and Related Conditions
University of Helsinki
2016-2025
Helsinki University Hospital
2013-2022
University of British Columbia
2020
Royal Women's Hospital
2009-2018
Institut National de Santé Publique du Québec
2010-2018
Murdoch Children's Research Institute
2018
University of Virginia
2018
Royal Children's Hospital
2018
Danish Cancer Society
2009-2018
Karolinska Institutet
2001-2017
Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV 6, 11, 16, (HPV-6/11/16/18) for the prevention high-grade lesions associated with HPV-16 HPV-18.
Human papillomavirus (HPV) has been associated with cervical intraepithelial neoplasia, but the temporal relation between infection and neoplasia remains unclear, as does relative importance of specific type HPV, other sexually transmitted diseases, risk factors.
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, genital warts. We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16-23 years) were enrolled in randomised, placebo-controlled study quadrivalent 6/11/16/18 L1 virus-like-particle vaccine with vaccination at months 0, 2, 6. At regular intervals through 3 years, subjects underwent gynaecologic examination, cervicovaginal sampling DNA,...
Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission HSV.We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic HSV-2 susceptible HSV-2. The partners infection were randomly assigned receive either 500 mg valacyclovir once daily or placebo for eight months. partner was evaluated monthly clinical signs symptoms herpes....
Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated.We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 genotyping performed biopsy samples, histological diagnoses were determined by a pathology panel. Analyses...
The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women they were "negative to 14 HPV types" mixed HPV-exposed -unexposed (intention-to-treat group).This analysis studied 17 622 aged 15-26 years who enrolled one two randomized, placebo-controlled, efficacy trials for HPV6/11/16/18 (first patient December 28, 2001, studies...
Objectives To evaluate the prophylactic efficacy of human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias anogenital warts (condyloma acuminata).
Among 100 randomly selected nonmenstruating women attending a clinic for sexually transmitted diseases, we assessed objective criteria the clinical diagnosis of mucopurulent cervicitis. Visualization yellow endocervical secretions on white swab and presence 10 or more polymorphonuclear leukocytes per microscopical field (at magnification 1000) in satisfactory gram-stained smears were independently correlated with cervical Chlamydia trachomatis infection. Neither finding gonorrhea genital...
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We an update on the efficacy of quadrivalent against high-grade lesions based end-of-study data three clinical trials. Additionally, we stratify by several baseline characteristics, including age, smoking status, Papanicolaou (Pap) test results. A total 18,174 females ages 16 26 years were randomized allocated into one trials...
To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on risk developing subsequent disease after an excisional procedure for cervical intraepithelial neoplasia or diagnosis genital warts, vulvar neoplasia, vaginal neoplasia.
Because menorrhagia is often a reason for seeking medical attention, it important to consider outcomes and costs associated with alternative treatment modalities. Both the levonorgestrel-releasing intrauterine system (LNG-IUS) hysterectomy have proven effective of but there are no long-term comparative studies measuring cost quality life.To compare outcomes, quality-of-life issues, LNG-IUS vs in menorrhagia.Randomized controlled trial conducted between October 1, 1994, 6, 2002, enrolling 236...
Cervical carcinoma is a sexually transmitted disease most strongly linked with human-papillomavirus (HPV) infection. We conducted prospective sero-epidemiologic study to evaluate the role of Chlamydia trachomatis infection in development cervical carcinoma, invasive cancer as an end point. A nested case-control within cohort 530000 Nordic women was performed. Linking data files 3 serum banks and registries Finland, Norway Sweden identified 182 diagnosed during mean follow-up 5 years after...
To define and quantitate histologic changes in the endometrium that best correlate with documented upper genital tract infection (UGTI) laparoscopically diagnosed acute salpingitis, we studied endometrial biopsy specimens from 69 consecutive patients clinically suspected pelvic inflammatory disease (PID) who underwent microbiological evaluation for UGTI laparoscopic examination salpingitis. Both confirmed salpingitis were present 37 (54%), without 1 (1%), 11 (16%), neither nor 20 (29%)....
BackgroundWe evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59) associated with >20% cancers. The population included HPV-naive women preexisting and/or HPV-related at enrollment MethodsPhase 3 efficacy studies enrolled 17,622 aged 16–26 years. Subjects underwent cervicovaginal sampling Pap testing day 1 then 6–12-month intervals for up 4 typing was performed...
PURPOSE: To assess the value of magnetic resonance (MR) imaging in diagnosis pelvic inflammatory disease (PID) and to compare MR with transvaginal ultrasonography (US) laparoscopy. MATERIALS AND METHODS: Thirty consecutive patients hospitalized because they were clinically suspected having PID underwent US T1-weighted spin-echo, T2-weighted turbo inversion-recovery at 1.5 T. All laparoscopy after imaging. RESULTS: was laparoscopically proved 21 (70%) patients. The agreed that obtained 20...